ABMD

Analyst Note: ABMD (Abiomed, Inc.)

Date: 2026-06-13 Current Price: $381.02

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 0.8% (Sub-threshold)

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, ABMD is classified as a Tactical, setup-led name. There is no named secular thesis active in the conviction stack for this specific date. The investment case must be judged strictly on the quality of the technical setup (which is currently absent) and the underlying business fundamentals. No macro or industry-specific secular themes (e.g., "Heart Failure Epidemic" as a primary driver) are being applied as a standalone conviction factor here; the focus remains on the structural readiness of the equity and the operational status of the business.

3. Business Overview

Company Profile: Abiomed, Inc. specializes in the creation and distribution of advanced medical technology designed to support or substitute the heart's pumping action in patients suffering from heart failure. The company also offers ongoing care for these individuals.

Product Portfolio & Technology:

• Impella Family: The core portfolio includes various devices from the Impella family.
• Impella SmartAssist: A platform leveraging optical sensors for precise pump placement and using algorithms to enhance native heart function assessment during patient weaning.
• Impella Connect: A system providing secure, cloud-based remote monitoring of the automated Impella controller for medical staff.
• OXY-1 System: A portable device for external respiratory support.

Distribution & Operations: The company distributes its products globally through dedicated direct sales and clinical support teams, reaching the United States, Japan, Canada, Europe (including Germany and France), Latin America, the Asia-Pacific, and the Middle East.

Corporate Status & Ownership: Crucially, as of the evidence date (2026-06-12), Abiomed has been operating as a subsidiary of Johnson & Johnson since December 22, 2022. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Management Expectations & Milestones (Recorded as of 2022-11-01): While the company is now a subsidiary, historical management expectations recorded during the acquisition process remain relevant to the structural timeline of the business:

• Transaction Completion: Management expected the transaction to be completed prior to the end of Q1 2023 (which has occurred).
• Financial Impact: Management projected the transaction would be "slightly dilutive to neutral to Johnson & Johnson's adjusted earnings per share in the first year and then accretive by approximately $0.05 in 2024 and increasingly accretive thereafter."
• Milestone Payments:
• $17.50 per share payable if net sales for Abiomed products exceed $3.7 billion during the period from Q2 2027 through Q1 2028 (or if met in a subsequent rolling 4-quarter period up to J&J Q1 2029).
• $7.50 per share payable upon FDA premarket application approval for Impella use in STEMI patients without cardiogenic shock by January 1, 2028.

4. Archetype and Conviction

Archetype: Growth Leader (Source: Layer A) Fit Analysis: The name fits the Growth Leader archetype based on its historical positioning as a pioneer in mechanical circulatory support and its integration into a larger healthcare giant (J&J) to accelerate global reach. The business model relies on high-margin medical device sales and recurring clinical support services.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: High (Strong historical data on product capabilities and acquisition terms; current status as a J&J subsidiary is confirmed).
• Structural Quality: Null. The setup is currently non-existent. The sub-threshold ATR (0.8%) indicates a lack of price action required to validate a "Growth Leader" breakout.
• Setup Readiness: None. The price is not in a forming coil, nor has it broken out.
• Rerating Potential: Unknown. Without a defined technical structure or a new catalyst (e.g., FDA approval of the STEMI indication mentioned in 2022 milestones), the rerating potential cannot be quantified from the current setup.

Valuation Context: No current valuation metrics (P/E, EV/EBITDA) are provided in the evidence base for 2026. The $381.02 price point must be viewed in the context of the 2022 acquisition terms, where milestone payments were tied to specific sales thresholds ($3.7B) and regulatory approvals.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Fundamental: Failure to meet the $3.7 billion sales threshold by the end of the relevant rolling period (Q1 2029) or failure to secure the FDA approval for the STEMI indication by January 1, 2028, would impact the milestone value structure recorded in 2022.

What Would Strengthen:

• Technical: A breakout above a defined resistance level with an ATR expanding into the 4–6% "sweet spot" range, confirming institutional interest.
• Fundamental: Confirmation of the $3.7 billion sales milestone achievement or the FDA approval of the STEMI indication, which would trigger the $17.50 or $7.50 per share milestone payments (if applicable to the current equity structure) or drive organic growth.

Gaps in Evidence:

• Current Financials: No 2026 revenue, margin, or cash flow data is available in the evidence base.
• Current Guidance: No management guidance for 2026 or 2027 is recorded.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Abiomed is a subsidiary of Johnson & Johnson since Dec 2022; no active technical coil structure exists; ATR is sub-threshold at 0.8%. Key risks: Lack of current financial data prevents valuation assessment; no technical breakout signal to justify entry; potential for prolonged consolidation due to low volatility. Sizing hint: Position size should be zero until a forming coil or confirmed breakout structure is established. Expected path: The stock will likely remain in a low-volatility range until a new catalyst (e.g., milestone achievement or new product data) triggers a structural re-rating and increased volatility. Expected horizon: Indefinite until technical structure forms or fundamental catalysts are realized. Failure mode to watch: A sustained period of low volatility combined with no fundamental news, indicating a lack of institutional interest or a "dead money" state.